The main goal of the project is the development of a new product capable of modulating the intestinal microbiota and immune function in breast cancer patients using an innovative mushroom culture and extraction process.

The product will be functionally validated in vitro and in vivo, in natural animal models of cancer (Centro Rof. Codina), and finally in a human trial. Study data will include classical biomarkers, omics, histological techniques, and the assessment of nociception to:

1. Allow a better understanding of the mechanisms and processes involving the intestinal microbiota in breast cancer.
2. Study whether the modulation of the microbiota promotes an improvement in the treatment of cancer and can prevent side effects of current treatments such as chemotherapy-associated neuropathy.

Clinical trial

The final part of the project will evaluate the efficacy and benefits of the new product on breast cancer patients’ health. In this study, the gut microbiota will be monitored using molecular multi-omic platforms.

Funding: the Microimmunomama project is funded by the Retos program.

Participating organisations: the project was initiated by Hifas da Terra in collaboration with the Leitat technology center, and the Fundación Biomédica Galicia Sur, which work out of hospitals in Vigo, Pontevedra, and Ourense.

The Galician companies Hifas da Terra, Cuevas and Cía and Algamar have started the Neurofood project. This is an R&D initiative to develop functional foods and food supplements from Galician foods of high nutritional value such as medicinal mushrooms, chestnuts and algae.

These have already confirmed the presence of certain triterpenoid compounds, vitamins, minerals and other essential nutrients that could affect aspects related to neurocognitive development and, specifically, with perception, memory, attention and learning.

Neurofood is a “comprehensive project” because it provides, after the research phases, the development of specific products and their functional validation in healthy individuals and patients, both early and advanced.

Project funded by the Galician Innovation Agency and developed with the support of the Ministry of Economy, Economy and Industry of the Xunta de Galicia.

• Budget: Hifas da Terra S.L. (310 303,29 €); Cuevas y Cía S.A. and Algamar.
• Approved subsidy: Hifas da Terra S.L. (186 181,97 €); Cuevas y Cía S.A. and Algamar.
• Collaborative project: Hifas da Terra, Cuevas y Cía, Algamar, Foltra Foundation, Anfaco-Cecopesca, Centro Tecnolóxico da Carne and University of Santiago de Compostela (USC).

Collaborative R & D project led by Hifas da Terra in which the relationship between the modulation of the intestinal microbiota and the progression of colorectal cancer will be evaluated, as well as the repercussions that the use of prebiotic and anti-inflammatory compounds derived from the fungi in the quality of life of cancer patients. This initiative has the support of the CDTI, the financing mediator of the general administration of the state of the business R + D + i.

• Budget: 686 € 409

Project for the industrial development of the cultivation of medicinal mushroom species to obtain new compounds with anticancer activity applicable in products aimed at the prevention and treatment of gastric and colorectal cancer.

• Overall budget of the project: 1 245,438 €
• Hifas da Terra global budget: 501 533 €
• Subsidy approved to Hifas da Terra: 300 919,80 €
• Collaborative project (call FEDER-INNTERCONECTA): Hifas da Terra, CZ Veterinary and Research Group in Clinical and Translational Oncology of the Biomedical Research Institute of A Coruña (INIBIC).

Pilot evaluation of the efficacy, safety and tolerability of a daily oral dose of an experimental Mycotherapy protocol in patients with osteoarthritis of the knee for three months.

Self-funded collaborative project: Hifas da Terra and the Osteoarthritis Foundation International (OAFI).

Back to the project menu >